Dec 31, 2025 • Business Wire
BEARISH
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)
Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) for potential securities fraud following two significant share price declines. The first decline occurred after a report by Scorpion Capital described Soleno's product, Vykat XR, as overpriced and potentially unsafe. The second drop followed Soleno's disclosure of a high discontinuation rate for Vykat XR due to adverse effects, which the CEO linked to the short seller report.
Dec 30, 2025 • ts2.tech
BEARISH
Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips
Soleno Therapeutics (SLNO) shares fell about 3% in afternoon trading after a "investor alert" from a law firm, Pomerantz LLP, revived scrutiny stemming from an earlier short-seller report. The alert highlighted potential claims against Soleno, linking back to an August 2025 report by Scorpion Capital that deemed Soleno’s drug Vykat XR overpriced and potentially unsafe. This decline highlights investor sensitivity to legal headlines and ongoing debates around Vykat XR's commercialization, pricing power, and patient adoption.
Dec 29, 2025 • WRIC ABC 8News
NEUTRAL
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (SLNO) following reports detailing concerns about its only product, Vykat XR, which led to significant stock price drops. The investigation comes after a Scorpion Capital report labeled Vykat XR overpriced and potentially unsafe, and subsequent quarterly earnings revealed high discontinuation rates due to adverse effects. Investors are encouraged to learn more and potentially assist in the investigation.
Dec 28, 2025 • CBS 17
BEARISH
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO) following reports that impacted its stock price. The investigation concerns potential claims for purchasers of Soleno securities after a Scorpion Capital report questioned the safety and pricing of Soleno's product, Vykat XR, and subsequent disclosures by Soleno about high discontinuation rates due to adverse effects. Investors are encouraged to learn more and potentially assist in the investigation.
Dec 28, 2025 • CBS 17
BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
Pomerantz LLP is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of its investors. This investigation follows a report by Scorpion Capital alleging Soleno's drug, Vykat XR, is overpriced and potentially unsafe, which caused significant drops in Soleno's stock price. Further price drops occurred after Soleno reported a high discontinuation rate for Vykat XR due to adverse effects, attributing it partly to the short seller report.
Dec 27, 2025 • KFOR.com
BEARISH
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Soleno Therapeutics, Inc. (NASDAQ: SLNO) purchasers following reports that their only product, Vykat XR, is overpriced and potentially unsafe. The investigation stems from a Scorpion Capital report and subsequent disclosures by Soleno regarding the high discontinuation rate of Vykat XR due to adverse effects. Shareholders are encouraged to contact the firm to learn more and potentially assist in the investigation.